CN102321158A - 阻止细胞dna合成抑制细胞增殖的多肽及用途 - Google Patents
阻止细胞dna合成抑制细胞增殖的多肽及用途 Download PDFInfo
- Publication number
- CN102321158A CN102321158A CN201110242869A CN201110242869A CN102321158A CN 102321158 A CN102321158 A CN 102321158A CN 201110242869 A CN201110242869 A CN 201110242869A CN 201110242869 A CN201110242869 A CN 201110242869A CN 102321158 A CN102321158 A CN 102321158A
- Authority
- CN
- China
- Prior art keywords
- cell
- polypeptide
- aspartic acid
- dna
- tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (6)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102428693A CN102321158B (zh) | 2011-08-23 | 2011-08-23 | 阻止细胞dna合成抑制细胞增殖的多肽及用途 |
PCT/CN2012/078378 WO2013026334A1 (zh) | 2011-08-23 | 2012-07-09 | 阻止细胞dna合成、抑制细胞增殖的多肽及其用途 |
ES12825332.5T ES2607648T3 (es) | 2011-08-23 | 2012-07-09 | Prevención de la síntesis de ADN celular y poliopédido de inhibición de la proliferación celular y uso de esto |
EP12825332.5A EP2749568B1 (en) | 2011-08-23 | 2012-07-09 | Cell dna synthesis prevention and cell proliferation inhibition polypeptide and use thereof |
US14/187,354 US20140179619A1 (en) | 2011-08-23 | 2014-02-24 | Polypeptide, nucleotide sequence thereof, and method for using the same for preventing dna synthesis and inhibiting cell proliferation |
US15/071,178 US9498510B2 (en) | 2011-08-23 | 2016-03-15 | Polypeptide, nucleotide sequence thereof, and method for using the same for preventing DNA synthesis and inhibiting cell proliferation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011102428693A CN102321158B (zh) | 2011-08-23 | 2011-08-23 | 阻止细胞dna合成抑制细胞增殖的多肽及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102321158A true CN102321158A (zh) | 2012-01-18 |
CN102321158B CN102321158B (zh) | 2013-03-27 |
Family
ID=45449014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011102428693A Active CN102321158B (zh) | 2011-08-23 | 2011-08-23 | 阻止细胞dna合成抑制细胞增殖的多肽及用途 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20140179619A1 (zh) |
EP (1) | EP2749568B1 (zh) |
CN (1) | CN102321158B (zh) |
ES (1) | ES2607648T3 (zh) |
WO (1) | WO2013026334A1 (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013026334A1 (zh) * | 2011-08-23 | 2013-02-28 | 常州德健生物科技有限公司 | 阻止细胞dna合成、抑制细胞增殖的多肽及其用途 |
CN104043102A (zh) * | 2014-03-28 | 2014-09-17 | 武汉益承生物科技股份有限公司 | 一种多肽在制备治疗核因子-κB异常活化疾病药物中的用途 |
CN106729609A (zh) * | 2016-12-16 | 2017-05-31 | 湖北工业大学 | N15多肽在制备细菌抑制剂中的用途 |
CN106729610A (zh) * | 2016-12-16 | 2017-05-31 | 湖北工业大学 | N15多肽在抑制金黄色葡萄球菌抑制剂中的用途 |
CN106818746A (zh) * | 2016-12-16 | 2017-06-13 | 湖北工业大学 | N15多肽在制备蓝藻抑制剂中的用途 |
CN107050421A (zh) * | 2016-12-16 | 2017-08-18 | 湖北工业大学 | N15多肽在制备真菌抑制剂中的用途 |
CN110882228A (zh) * | 2019-11-29 | 2020-03-17 | 南京禾瀚医药科技有限公司 | 一种伊匹乌肽肠溶制剂 |
CN111803619A (zh) * | 2020-07-26 | 2020-10-23 | 武汉益承生物科技有限公司 | 多肽在制备创伤治疗药物中的用途 |
CN111956781A (zh) * | 2019-05-20 | 2020-11-20 | 武汉益承生物科技有限公司 | 一种多肽在治疗眼部炎症药物中的应用 |
CN118370805A (zh) * | 2024-04-29 | 2024-07-23 | 广州美达康生物医药科技有限公司 | 一种抑菌妇科凝胶及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1565621A (zh) * | 2003-07-07 | 2005-01-19 | 夏献民 | 抑制细胞生长的多肽的获得及用途 |
CN101016340A (zh) * | 2007-01-18 | 2007-08-15 | 夏献民 | 融合多肽及其在肿瘤与细胞生长异常相关的疾病治疗中的用途 |
CN101244258A (zh) * | 2008-03-21 | 2008-08-20 | 夏献民 | Tat-n25多肽在治疗银屑病等细胞生长异常皮肤病中的用途 |
CN101759812A (zh) * | 2009-12-28 | 2010-06-30 | 中国药科大学 | 一种新型仿穿膜肽结构的壳聚糖衍生物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US20080014598A1 (en) * | 2006-07-13 | 2008-01-17 | Cell Signaling Technology, Inc. | Phospho-specific antibodies to pi3k regulatory subunit and uses thereof |
TW200831536A (en) * | 2006-11-29 | 2008-08-01 | Genentech Inc | Method of diagnosing and treating glioma |
CN101100679A (zh) * | 2007-05-24 | 2008-01-09 | 夏献民 | 一种表达抑制细胞生长多肽的腺病毒的构建及其应用 |
CN102321158B (zh) * | 2011-08-23 | 2013-03-27 | 常州德健生物科技有限公司 | 阻止细胞dna合成抑制细胞增殖的多肽及用途 |
-
2011
- 2011-08-23 CN CN2011102428693A patent/CN102321158B/zh active Active
-
2012
- 2012-07-09 ES ES12825332.5T patent/ES2607648T3/es active Active
- 2012-07-09 WO PCT/CN2012/078378 patent/WO2013026334A1/zh active Application Filing
- 2012-07-09 EP EP12825332.5A patent/EP2749568B1/en active Active
-
2014
- 2014-02-24 US US14/187,354 patent/US20140179619A1/en not_active Abandoned
-
2016
- 2016-03-15 US US15/071,178 patent/US9498510B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1565621A (zh) * | 2003-07-07 | 2005-01-19 | 夏献民 | 抑制细胞生长的多肽的获得及用途 |
CN101016340A (zh) * | 2007-01-18 | 2007-08-15 | 夏献民 | 融合多肽及其在肿瘤与细胞生长异常相关的疾病治疗中的用途 |
CN101244258A (zh) * | 2008-03-21 | 2008-08-20 | 夏献民 | Tat-n25多肽在治疗银屑病等细胞生长异常皮肤病中的用途 |
CN101759812A (zh) * | 2009-12-28 | 2010-06-30 | 中国药科大学 | 一种新型仿穿膜肽结构的壳聚糖衍生物 |
Non-Patent Citations (3)
Title |
---|
《中华实验外科杂志》 20061031 王晶等 N24p55gammaPI3K靶向抑制胃癌细胞增殖的研究 1221-1223 1-6 第23卷, 第10期 * |
ASHOK CHAUHAN等: "The Taming of the Cell Penetrating Domain of the HIV Tat: Myths and Realities", 《J CONTROL RELEASE》 * |
王晶等: "N24p55γPI3K靶向抑制胃癌细胞增殖的研究", 《中华实验外科杂志》 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013026334A1 (zh) * | 2011-08-23 | 2013-02-28 | 常州德健生物科技有限公司 | 阻止细胞dna合成、抑制细胞增殖的多肽及其用途 |
CN104043102A (zh) * | 2014-03-28 | 2014-09-17 | 武汉益承生物科技股份有限公司 | 一种多肽在制备治疗核因子-κB异常活化疾病药物中的用途 |
CN104043102B (zh) * | 2014-03-28 | 2017-04-19 | 武汉益承生物科技股份有限公司 | 一种多肽在制备治疗核因子‑κB异常活化疾病药物中的用途 |
CN106729609B (zh) * | 2016-12-16 | 2021-04-09 | 湖北工业大学 | N15多肽在制备细菌抑制剂中的用途 |
CN106729609A (zh) * | 2016-12-16 | 2017-05-31 | 湖北工业大学 | N15多肽在制备细菌抑制剂中的用途 |
CN106729610A (zh) * | 2016-12-16 | 2017-05-31 | 湖北工业大学 | N15多肽在抑制金黄色葡萄球菌抑制剂中的用途 |
CN106818746A (zh) * | 2016-12-16 | 2017-06-13 | 湖北工业大学 | N15多肽在制备蓝藻抑制剂中的用途 |
CN107050421A (zh) * | 2016-12-16 | 2017-08-18 | 湖北工业大学 | N15多肽在制备真菌抑制剂中的用途 |
CN106818746B (zh) * | 2016-12-16 | 2019-08-20 | 湖北工业大学 | N15多肽在制备蓝藻抑制剂中的用途 |
CN111956781B (zh) * | 2019-05-20 | 2023-11-17 | 益承康泰(厦门)生物科技有限公司 | 一种多肽在治疗眼部炎症药物中的应用 |
CN111956781A (zh) * | 2019-05-20 | 2020-11-20 | 武汉益承生物科技有限公司 | 一种多肽在治疗眼部炎症药物中的应用 |
CN110882228A (zh) * | 2019-11-29 | 2020-03-17 | 南京禾瀚医药科技有限公司 | 一种伊匹乌肽肠溶制剂 |
CN113368214A (zh) * | 2020-07-26 | 2021-09-10 | 武汉益承生物科技有限公司 | 多肽在制备创伤治疗药物中的用途 |
WO2022022475A1 (zh) * | 2020-07-26 | 2022-02-03 | 武汉益承生物科技有限公司 | 多肽在制备创伤治疗药物中的用途 |
CN111803619A (zh) * | 2020-07-26 | 2020-10-23 | 武汉益承生物科技有限公司 | 多肽在制备创伤治疗药物中的用途 |
CN118370805A (zh) * | 2024-04-29 | 2024-07-23 | 广州美达康生物医药科技有限公司 | 一种抑菌妇科凝胶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
US9498510B2 (en) | 2016-11-22 |
ES2607648T3 (es) | 2017-04-03 |
US20140179619A1 (en) | 2014-06-26 |
EP2749568A9 (en) | 2015-12-09 |
EP2749568A1 (en) | 2014-07-02 |
EP2749568A4 (en) | 2015-05-20 |
WO2013026334A1 (zh) | 2013-02-28 |
CN102321158B (zh) | 2013-03-27 |
US20160303183A1 (en) | 2016-10-20 |
EP2749568B1 (en) | 2016-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102321158B (zh) | 阻止细胞dna合成抑制细胞增殖的多肽及用途 | |
Shiravand et al. | Immune checkpoint inhibitors in cancer therapy | |
Golán et al. | NK cell-based glioblastoma immunotherapy | |
Yazdanifar et al. | Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma | |
Zhou et al. | Myofiber necroptosis promotes muscle stem cell proliferation via releasing Tenascin-C during regeneration | |
CN101016340A (zh) | 融合多肽及其在肿瘤与细胞生长异常相关的疾病治疗中的用途 | |
CN104043102B (zh) | 一种多肽在制备治疗核因子‑κB异常活化疾病药物中的用途 | |
CN110418839A (zh) | 用于临床的修饰的NK-92 haNK003细胞 | |
CN106544365A (zh) | 一种人抗cd19嵌合抗原受体修饰的cik的制备方法及应用 | |
CN110343665A (zh) | 一种新型car-t细胞及其应用 | |
CN109913422A (zh) | 一种包含肿瘤抗原识别受体的免疫细胞及其应用 | |
Mohr et al. | MSC. sTRAIL has better efficacy than MSC. FL-TRAIL and in combination with AKTi blocks pro-metastatic cytokine production in prostate cancer cells | |
CN108300699A (zh) | 修饰的nk细胞及其用途 | |
Klapdor et al. | NK cell-mediated eradication of ovarian cancer cells with a novel chimeric antigen receptor directed against CD44 | |
CN106222141B (zh) | Nk细胞培养液和细胞培养方法 | |
CN108367049A (zh) | Pkm2调节剂和hmgb1的组合制剂 | |
Singh et al. | Enhancing T cell chemotaxis and infiltration in glioblastoma | |
Qian et al. | Dual-aptamer-engineered M1 macrophage with enhanced specific targeting and checkpoint blocking for solid-tumor immunotherapy | |
Newport et al. | Improved immunotherapy efficacy by vascular modulation | |
Li et al. | SPAG6 regulates cell apoptosis through the TRAIL signal pathway in myelodysplastic syndromes | |
Maiorova et al. | Natural Flt3Lg-based chimeric antigen receptor (Flt3-CAR) T cells successfully target Flt3 on AML cell lines | |
Codenotti et al. | Hyperactive Akt1 signaling increases tumor progression and DNA repair in embryonal rhabdomyosarcoma RD line and confers susceptibility to glycolysis and mevalonate pathway inhibitors | |
Jin et al. | NK cells lose their cytotoxicity function against cancer stem cell-rich radiotherapy-resistant breast cancer cell populations | |
Wang et al. | Chlorotoxin targets ERα/VASP signaling pathway to combat breast cancer | |
Rechberger et al. | Exploring the molecular complexity of medulloblastoma: implications for diagnosis and treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUHAN YICHENG BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: CHANGZHOU DEJIAN BIOLOGY TECHNOLOGY CO., LTD. Effective date: 20150312 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 213000 CHANGZHOU, JIANGSU PROVINCE TO: 430074 WUHAN, HUBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150312 Address after: 430074, B1 building, Optics Valley biological city, 666 hi tech Avenue, East Lake Development Zone, Hubei Patentee after: Yi Cheng biotech inc, Wuhan Address before: 213000 North Zone, Innovation Zone, science and Technology Park, Changzhou hi tech Zone, Jiangsu, A-453 Patentee before: Changzhou Dejian Biological Technology Co., Ltd. |